Compare Ascendis Pharma A/S (ASND) vs Funko Inc (FNKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Funko Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Funko Inc trades at $5.48 (market cap $311.58M). The key difference: Ascendis Pharma A/S is far larger — about 56.9× Funko Inc's market cap. Which is the better fit depends on your goals.
| ASND | FNKO | |
|---|---|---|
Market Cap | $17.74B | $311.58M |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $5.88 |
52-Week Low | $163.32 | $2.46 |
Enterprise Value | $18.11B | $556.62M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
FNKO trades at $5.58, up 3.91% with a neutral technical signal despite bullish moving averages. The company shows mixed fundamentals with revenue declining to $908M in 2025 and a net loss of $67M, though recent quarters beat EPS estimates. Analyst consensus is divided with 42.9% buy ratings, while positive news includes new product launches and Q1 2026 revenue growth to $200.9M. Cash flow improved to a net positive $7.5M in 2025 from negative trends in prior years.
Outlook remains cautious due to persistent losses and high debt, but recent execution improvements and product innovation offer potential upside. Key risks include margin pressure and competitive threats in the collectibles market. Investors should weigh the bullish analyst sentiment against fundamental challenges before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
